ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO130

Onconephrology, an Essential Subspecialty: Experience of a University Hospital Center

Session Information

Category: Onconephrology

  • 1600 Onconephrology

Authors

  • Bermejo, Sheila, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Bolufer, Mónica, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Viggiano, Davide, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
  • Callejo, Ana, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • López-Martínez, Marina, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Vergara, Ander, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Agraz, Irene, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Bestard, Oriol, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Soler, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
Background

Kidney complications of cancer patients and cancer in renal patients have increased in recent years. This study evaluates the characteristics of the patients referred to the Onco-Nephrology Unit from January 2021 to December 2021, studying the cognitive and mood status of these patients.

Methods

This is a prospective observational study of the Onco-Nephrology consultation at our hospital during 2021. Clinical and analytical characteristics of the patients and clinical indication for referral were analyzed. In addition, sleep quality, mood and cognitive status were assessed using validated rating scales(Epsworth, Geriatric Depression Scale and Montreal).

Results

Seventy-four patients were evaluated, mean age was 69.6(±11) years, 41(55.4%) men, 47(63.5%) had hypertension, 18(24.3%) diabetics, and 11(14.9%) were affected by heart disease. In addition, creatinine 1.93(±1.1)mg/dl, eGFR 39.97(±20.3)mL/min, proteinuria 187[29-515.9]mg/g, and 4(5.4%) had microhematuria. The most frequent cancers were intestinal, gynecological and mammary with 12.16%(n=9) each. 58.3%(n=42) of patients had metastatic disease. 48.7%(n=36) received chemotherapy and 58.1%(n=43) targeted therapies. Platinum was the most frequently used chemotherapy and anti-VEGF in terms of targeted therapies. The most frequent clinical indication for referral was acute renal failure(n=36;48.7%). Rating scales were obtained in 51 patients: 49%(n=25) were snorers, followed by 17.6%(n=9) with insomnia and 11.8%(n=6) with OSAS. 27 patients(36.5%) had cognitive impairment. Mild depression was detected in 13 cases(25.5%) and moderate depression in 11.6%(n=6). 21 renal biopsies were performed, the most frequent diagnosis was acute interstitial nephritis(71.4%, n=15) followed by thrombotic microangiopathy(19% n=4).A total of 15 patients(20.3%) died during the year.

Conclusion

Most patients referred to Onco-Nephrology are affected by advanced oncological disease and consequently had a high mortality.The most frequent indication for referral was acute kidney injury(48.7%). Comprehensive patient care is important, given the prevalence of depressive syndrome.Onco-Nephrology is an example of a comprehensive and multidisciplinary approach to improve the survival and quality of life of patients with advanced cancer and renal disease.